Deep brain stimulation of the medial forebrain bundle for treatment-resistant depression - a narrative literature review.
Angelika Stapińska-SyniecAngelika Stapińska-SyniecPublished in: Postepy psychiatrii neurologii (2021)
The current clinical data of MFB DBS are limited by small sample size and the small number of clinical open-label trials. There is an urgent need for more clinical trials targeting the MFB for TRD. The results obtained in these studies showed a very rapid antidepressant effect observed within one week after the start of stimulation. MFB DBS for TRD should be considered as a last resort treatment due to its invasive character. However, this treatment may be a promising alternative for TRD patients.
Keyphrases
- deep brain stimulation
- clinical trial
- parkinson disease
- open label
- obsessive compulsive disorder
- end stage renal disease
- randomized controlled trial
- chronic kidney disease
- newly diagnosed
- combination therapy
- depressive symptoms
- major depressive disorder
- peritoneal dialysis
- phase iii
- big data
- machine learning
- squamous cell carcinoma
- phase ii study
- cancer therapy
- replacement therapy
- sleep quality